# Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

> **NCT02587650** · PHASE2 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 1 (actual)

## Conditions studied

- ALK Fusion Protein Expression
- BRAF wt Allele
- Invasive Skin Melanoma
- MET Fusion Gene Positive
- NRAS wt Allele
- NTRK1 Fusion Positive
- NTRK2 Fusion Positive
- NTRK3 Fusion Positive
- RET Fusion Positive
- ROS1 Fusion Positive
- Stage III Cutaneous Melanoma
- Stage IIIA Cutaneous Melanoma
- Stage IIIB Cutaneous Melanoma
- Stage IIIC Cutaneous Melanoma
- Stage IV Cutaneous Melanoma

## Interventions

- **DRUG:** Capmatinib
- **DRUG:** Ceritinib
- **DRUG:** Entrectinib
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT02587650
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03-26
- **Primary completion:** 2018-07-12
- **Final completion:** 2018-07-12
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Funding
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02587650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02587650, "Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02587650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*